These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 3622947)

  • 1. The safety profile of De-Nol.
    Bader JP
    Digestion; 1987; 37 Suppl 2():53-9. PubMed ID: 3622947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
    Wagstaff AJ; Benfield P; Monk JP
    Drugs; 1988 Aug; 36(2):132-57. PubMed ID: 3053124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor (EGF) in the gastroprotective and ulcer healing actions of colloidal bismuth subcitrate (De-Nol) in rats.
    Konturek SJ; Dembinski A; Warzecha Z; Bielanski W; Brzozowski T; Drozdowicz D
    Gut; 1988 Jul; 29(7):894-902. PubMed ID: 3260885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colloidal bismuth subcitrate in peptic ulcer--a review.
    Tytgat GN
    Digestion; 1987; 37 Suppl 2():31-41. PubMed ID: 3305117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Assessment of the efficacy of de-nol and bismuth subnitrate treatment of patients with associated peptic ulcer and pyloric Helicobacter infection (experimental and clinical studies)].
    Il'chenko AA; Zurabishvili NG; Zhukhovitskiĭ BG; Gorodinskaia VS
    Ter Arkh; 1991; 63(2):21-6. PubMed ID: 2048016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Present and future treatment of peptic ulcer and potential role of DE-NOL.
    Scand J Gastroenterol Suppl; 1982; 80():49-57. PubMed ID: 6761852
    [No Abstract]   [Full Text] [Related]  

  • 7. Colloidal bismuth subcitrate in peptic ulcer disease.
    Tytgat GN
    S Afr Med J; 1986 Jul; 70(1):31-3. PubMed ID: 3523793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of De-Nol].
    Tomecki R; Habior A; Medrzejewski W
    Pol Tyg Lek; 1984 Sep; 39(37):1247-8. PubMed ID: 6390386
    [No Abstract]   [Full Text] [Related]  

  • 9. [Therapy of peptic ulcer and chronic gastritis with bismuth salts].
    Rösch W
    Z Gastroenterol; 1987 Sep; 25 Suppl 4():34-40. PubMed ID: 3687149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the gastroprotective and ulcer-healing effects of colloidal bismuth subcitrate.
    Konturek SJ; Radecki T; Piastucki I; Drozdowicz D
    Digestion; 1987; 37 Suppl 2():8-15. PubMed ID: 3622948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Likelihood of relapse of duodenal ulcer after initial treatment with cimetidine or colloidal bismuth subcitrate.
    Miller JP; Hollanders D; Ravenscroft MM; Tweedle DE; Martin DF
    Scand J Gastroenterol Suppl; 1982; 80():39-42. PubMed ID: 6761851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Colloidal bismuth subcitrate (de-nol) in the treatment of peptic ulcer].
    Grigo'rev PIa; Isakov VA; Iakovenko EP
    Klin Med (Mosk); 1989 May; 67(5):17-22. PubMed ID: 2671482
    [No Abstract]   [Full Text] [Related]  

  • 13. [De-nol in NSAID-induced gastroduodenal lesions].
    Cataldo MG; D'Aiuto A; Bongiorno A
    Minerva Dietol Gastroenterol; 1990; 36(1):27-30. PubMed ID: 2186304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De-Nol: a new concept in cytoprotection. Proceedings from an international symposium. Milan, Italy, 13 November 1985.
    Scand J Gastroenterol Suppl; 1986; 122():1-53. PubMed ID: 3465025
    [No Abstract]   [Full Text] [Related]  

  • 15. [Characteristics of the effects of de-nol on the course of erosive-ulcerative lesions of the esophagus, stomach and duodenum associated with Helicobacter pylori].
    Grebenev AL; Miagkova LP; Golochevskaia VS; Lapina TL; Sklianskaia OA
    Klin Med (Mosk); 1995; 73(2):34-7. PubMed ID: 7609414
    [No Abstract]   [Full Text] [Related]  

  • 16. Maintenance therapy with colloidal bismuth subcitrate in duodenal ulcer disease.
    Bianchi Porro G; Lazzaroni M; Cortvriendt WR
    Digestion; 1987; 37 Suppl 2():47-52. PubMed ID: 3305118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bismuth is better.
    Tytgat GN
    Scand J Gastroenterol Suppl; 1988; 155():16-7. PubMed ID: 3244996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of qid and bd administration of De-Nol in the short term treatment of duodenal ulcer.
    Lazzaroni M; Petrillo M; Bianchi Porro G
    Br J Clin Pract; 1989 Apr; 43(4):151-5. PubMed ID: 2590626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sucralfate and other non-antisecretory agents in the treatment of peptic ulcer disease.
    May B
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():113-6. PubMed ID: 2657280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topically active drugs in the treatment of peptic ulcers. Focus on colloidal bismuth subcitrate and sucralfate.
    Bianchi Porro G; Parente F
    J Clin Gastroenterol; 1992 Apr; 14(3):192-8. PubMed ID: 1348753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.